Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company is headquartered in Toronto, Canada.

Awakn Life Sciences Corp.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Mind Medicine (MindMed) Inc.

Awakn Life Sciences is a clinical stage biotechnology company developing therapeutics for substance use and mental health disorders. The company focuses on medications for Alcohol Use Disorder and aims to provide evidence-based treatments to addiction sufferers.

Metric
Company Name	Awakn Life Sciences Corp.	Mind Medicine (MindMed) Inc.
Symbol	AWKN	MNMD
MSH ID	COM:AWAKNLIFESCIENCES	CO:MINDMED
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	CA	CA
Stage		Post-IPO Equity
Employee Count	44	57
Website	awaknlifesciences.com	mindmed.co
LinkedIn
Founders

Metric
Market Cap	3.14M	500.56M
Enterprise Value
Monthly Web Traffic		17.91K
Web Traffic Growth		-0.36
Valuation
Raised Capital		75M

Metric
Revenue	1.06M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-1.10M
EBITDA	-6.08M
Operating Income	-6.50M
Net Income	-6.47M
EPS	-0.25
Diluted EPS	-0.25
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.81
Operating Profit Margin	-6.37
EBITDA Margin	-5.74
Net Profit Margin	-6.41
Return on Equity	13.52
Return on Assets	-6.09
Return on Capital Employed	6.96

COM:AWAKNLIFESCIENCES

Awakn Life Sciences

Last Close

0.14

12/02 20:59

Market Cap

4.44M

Beta: -

Volume Today

7.32K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.64
P/B Ratio	-4.51
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.28
EV Multiple	-0.78

Metric
Days Sales Outstanding	120.95
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	120.95
Cash Conversion Cycle	-193.31
Asset Turnover	0.95

Metric
Operating Cash Flow	-5.21M
Free Cash Flow	-5.28M
Cash Flow to Debt	4.69
Operating Cash Flow/Sales	-7.31
Free Cash Flow Yield	-1.42

Metric
Cash & Equivalents	389.67K
Accounts Receivable	-10.98K
Inventory
Goodwill
Debt to Capitalization	0.63
Debt to Assets
Current Ratio	0.51
Quick Ratio	0.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.90
R&D to Revenue	0.90
SG&A to Revenue	3.41